81310 NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants

Name of the Procedure:

NPM1 (Nucleophosmin) Gene Analysis, Exon 12 Variants

Summary

The NPM1 gene analysis is a genetic test that looks for specific changes or mutations in exon 12 of the NPM1 gene. This gene is often mutated in cases of acute myeloid leukemia (AML), and its analysis can help in diagnosing and guiding the treatment of this type of leukemia.

Purpose

This test addresses the need to diagnose acute myeloid leukemia (AML) and to determine the presence of specific genetic mutations that can influence the treatment plan. The goal is to provide accurate diagnosis and personalized treatment strategies.

Indications

• Patients suspected of having acute myeloid leukemia (AML).
• Individuals who have been diagnosed with AML but need further genetic characterization to guide treatment.
• Patients with unexplained blood abnormalities or symptoms suggestive of leukemia, such as fatigue, easy bruising, and infections.

Preparation

• No specific fasting or medication adjustments are usually required.
• A blood sample will be needed, so staying hydrated can be helpful.
• Informing the healthcare provider of any medications or supplements being taken.

Procedure Description

1. Sample Collection: A blood sample or bone marrow aspirate is collected from the patient.
2. Laboratory Processing: The sample is sent to a laboratory where DNA is extracted.
3. Genetic Analysis: Using specialized techniques such as PCR (Polymerase Chain Reaction), the laboratory technicians analyze exon 12 of the NPM1 gene for the presence of mutations.
4. Reporting: Results are interpreted by a geneticist and reported back to the physician for clinical correlation and management.

Duration

The sample collection takes about 10-15 minutes. The overall time from sample collection to receiving results can vary, typically taking 1 to 2 weeks.

Setting

The sample collection can be performed in an outpatient clinic, hospital, or specialized laboratory.

Personnel

• Phlebotomist or nurse for sample collection.
• Laboratory technicians and geneticists for sample processing and analysis.
• Oncologist or hematologist for interpreting the results and managing treatment.

Risks and Complications

• Minor discomfort or bruising at the sample collection site.
• Rare risk of infection or prolonged bleeding at the puncture site.
• Psychological impact of receiving genetic test results.

Benefits

• Accurate diagnosis of acute myeloid leukemia (AML).
• Identification of specific genetic mutations that can guide personalized treatment plans.
• Better overall management and prognosis of the disease.

Recovery

• No significant recovery time is needed post-sample collection.
• Patients can resume normal activities immediately.
• Follow-up appointments will depend on the results and subsequent treatment plans.

Alternatives

• Cytogenetic analysis: Examines chromosomes for abnormalities but may not detect specific NPM1 mutations.
• Flow cytometry: Used to analyze physical and chemical characteristics of cells or particles, but not suitable for detecting genetic mutations.
• Bone marrow biopsy: More invasive but can provide additional information about the leukemia.

Patient Experience

During the sample collection, the patient may experience a quick needle prick similar to a routine blood draw. Post-procedure discomfort is usually minimal and can be managed with simple measures like applying pressure and a bandage to the puncture site. Emotional support may be needed when discussing test results and treatment options.